Q&A with Steve Strickland, Sensient
Steve Strickland, general manager of Sensient Pharmaceutical Coating Systems, on recent industry trends.
Q&A with Steve Strickland, general manager of Sensient Pharmaceutical Coating Systems
PharmTech:
What is the biggest industry challenge you're now facing?
Strickland:
A major challenge is maintaining continuous scientific innovation to meet the product demands of our customers. We are constantly looking for opportunities to expand our technical expertise and service either through internal development or acquisition.
I think that the consolidation within the pharmaceutical industry we serve will continue to play a role in our growth. Consolidation often brings personnel change, accompanied by shifts in the direction of research and development. We need to evolve along with our customers based on their changing needs.
PharmTech:
How do you stay abreast of new developments in the industry?
Strickland:
Our primary method of staying on top of industry developments is listening to our customers. Also, trade shows and trade publications are an excellent source of emerging industry trends, and we'll continue to rely on them.
PharmTech:
Do you see a new industry trend emerging?
Strickland:
Yes, the trend toward globalization of our industry continues to gain momentum. For example, the emergence of global markets, the multinational presence of pharmaceutical companies, and the location of manufacturing sites around the world demand an increased knowledge of the accompanying regulatory requirements.
PharmTech:
What is the most common demand your clients are currently making of you?
Strickland:
They demand high product quality. In an industry that is constantly under scrutiny, our customers demand excellence in the quality and performance of our products.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
